Pioglitazone: profile and news

Pioglitazone Has Cholesterol Advantages Versus Rosiglitazone in ... May 2, 2006
CHICAGO, IL -- May 2, 2006 -- A new study shows that pioglitazone and rosiglitazone exert significantly different effects on lipid metabolism and potential ... - DG News

Higher Risk Patients Benefit More After Conversion from ... May 3, 2006
CHICAGO, IL -- May 3, 2006 -- A new study shows that conversion from rosiglitazone to pioglitazone while maintaining statin therapy, improves the lipid ... - DG News

ERRATUM: Higher Risk Patients Benefit More After Conversion from ... May 5, 2006
There was an error in the title of our DG Dispatch (May 4, 2006) based on a presentation at the American Association of Clinical Endocrinologists (AACE) annual ... - DG News

Takeda Eyeing Prescription Drug Sales of 1.4 Tril. Yen By FY 2010 May 11, 2006
Among the four strategic drugs, consolidated sales of Pioglitazone, used to treat diabetes, rose 26.3 percent to 243.8 billion yen, and those of the anti ... - International News Service,

Adverse Events Related to Muraglitazar Use in Diabetes May 2, 2006
In the Proactive study 3 evaluating pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes, approximately 10% of ... - Journal of American Medical Association (subscription),

Takeda Announces "2006-2010 Medium-Term Management Plan" - Growth ... May 11, 2006
Leuprorelin, Lansoprazole, Candesartan and Pioglitazone Focusing on Takeda-ism, which represents the corporate philosophy referring to "Integrity = fairness ... - PharmaLive.com (press release),

Women Gain More Weight Than Men When Taking Thiazolidinedione ... May 3, 2006
...reviewed the charts of 100 outpatients in an endocrinology practice who had received or were receiving the thiazolidinediones pioglitazone or rosiglitazone as ... - DG News

Adverse Events Related to Muraglitazar Use in Diabetes—Reply May 2, 2006
The efficacy data showed effects on glycohemoglobin levels and lipids that were no better than the existing PPAR- agent pioglitazone. ... - Journal of American Medical Association (subscription),

Lilly Reports Q1 EPS of $.77, or 13% Growth Apr 20, 2006
Actos(R) (pioglitazone hydrochloride, Takeda), Takeda Alimta(R) (pemetrexed, Lilly) Arxxant(TM) (ruboxistaurin mesylate, Lilly) Byetta(R) (exenatide injection ... - MSN Money

Japan's Takeda, Eli Lilly end joint sales of diabetes drug in US Apr 20, 2006
Takeda said it will now take over all marketing and sales responsibilities of Actos or pioglitazone in the US as agreed back in 1998. ... - Forbes

ABL Bio Technologies launches Invia Health Apr 20, 2006
...fine tune the management of the disease needs of the patients- Glimepiride (GLIMOD), Glimepiride with Metformin (Glimod-M) and Pioglitazone with Metformin ... - Myiris.com,

ABL Biotech's pharma division Apr 29, 2006
Glimepiride (GLIMOD), Glimepiride with Metformin (GLIMOD-M) and Pioglitazone with Metformin (GLYSENSE) are some of the OHAs in the basket apart from Eunerv & ... - Chennai Online,

Newer Diabetic Meds Cost More, But Users Have Fewer Hospital ... Apr 28, 2006
TZDs (pioglitazone and rosiglitazone, brand names Actos and Avandia, respectively), were approved by the Food and Drug Administration in the late 1990s. ... - eMaxHealth.com,

Zydus Cadila files IND application for NME - ZYH2 Apr 24, 2006
In recent times, glitazones (rosiglitazone and pioglitazone) have been launched to treat increasing prevalence of insulin resistance in Type - II diabetes. ... - Express Pharma,

Other information

Indication
Treatment of Type II diabetes mellitus

Pharmacology
Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.

Mechanism Of Action
Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone enhances tissue sensitivity to insulin.

Drug Category
Hypoglycemic Agents; Thazolidinediones; ATC:A10BG03

Brand Names/Synonyms
AD-4833; Actos; Actost; CHEMBANK3906; Pioglitazona [Inn-Spanish]; Pioglitazone; Pioglitazone Hydrochloride; Pioglitazone [Ban:Inn]; Pioglitazonum [Inn-Latin]

Dosage Forms
Oral tablets

Absorption
Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.

Interactions
-->Interactions for Pioglitazone:

In vivo drug-drug interaction studies have suggested that pioglitazone may be a weak inducer of CYP 450 isoform 3A4 substrate.

Chemical IUPAC Name
5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione

Chemical Formula
C19H20N2O3S

Half Life
3-7 hours

Drug Type
Approved Drug

# Accession No
APRD00653

CAS Registry Number
111025-46-8